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Abstract
Global Salmonella infection, especially in developing countries, is a health and economic burden. The use of antibiotic drugs in
treating the infection is proving less effective due to the alarming rise of antibiotic-resistant strains of Salmonella, the effects of
antibiotics on normal gut microflora and antibiotic-associated diarrhoea, all of which bring a growing need for alternative
treatments, including the use of probiotic micro-organisms. However, there are issues with probiotics, including their potential
to be opportunistic pathogens and antibiotic-resistant carriers, and their antibiotic susceptibility if used as complementary
therapy. Clinical trials, animal trials and in vitro investigations into the prophylactic and therapeutic efficacies of probiotics have
demonstrated antagonistic properties against Salmonella and other enteropathogenic bacteria. Nonetheless, there is a need for
further studies into the potential mechanisms, efficacy and mode of delivery of yeast probiotics in Salmonella infections. This
review discusses Salmonella infections and treatment using antibiotics and probiotics.
INTRODUCTION
The global burden of morbidity and mortality from human
enteric pathogenic bacteria, including Salmonella species, is
immense, despite the presence of antibiotic drugs [1–3].
Research has estimated that Salmonella infection causes
2.8 billion cases of diarrhoea annually worldwide. Salmonella
enterica serovar Typhi (S. Typhi), the causative agent of
typhoid fever, is reported to cause 16–33million infectious
cases, with an estimated 500 000 to 600 000 deaths, while non-
typhoidal Salmonella (NTS) infections account for 90million
cases and 155 000 deaths worldwide annually [4]. The inci-
dence of Salmonella infections has been exacerbated by the
high prevalence of human immunodeficiency virus (HIV)
infections in Africa, and it has been reported that there are
2000–7500 Salmonella infection cases per 100 000 HIV-
infected adults [5]. In Australia, 127 195 cases of Salmonella
infection were reported to the National Notifiable Diseases
Surveillance System (NNDSS) from 2000 to 2013; however,
the real cases of salmonellosis were underestimated, as it has
been assumed that for every case of Salmonella infection
reported, there are seven cases of salmonellosis in the commu-
nity that have not been reported [6]. In 2010, Australia
reported 40 000 salmonellosis cases, 2100 hospitalizations,
6750 complications and 15 deaths [6]. In the USA, Salmonella
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is the leading cause of foodborne infections and associated
medical costs amounted to $2.17 billion (for 1.4million
infections) in 2010 [7]. Bloodstream infections caused by
Salmonella enterica in Asia accounted for 30% of all commu-
nity-acquired infections [8], while in Africa 29.1% of commu-
nity-acquired bloodstream infections were attributed to the
same Salmonella species [9].
Antibiotics are becoming less effective against some bacte-
rial pathogens, such as typhoidal Salmonella strains, and the
rise of antibiotic-resistant bacteria means that there is a
need for novel ways of preventing or treating infections
caused by enteric pathogenic bacteria [10]. Studies on pro-
biotics-based treatment/complementary treatment of Heli-
cobacter pylori and Clostridium difficile have long been
recognized as efficacious [11].
Probiotics are defined by the World Health Organization
(WHO) and Food and Agriculture Organization (FAO) as
‘live micro-organisms which when administered in adequate
amounts confer a health benefit on the host’ [12]. Species of
Lactobacillus and Bifidobacterium are the most commonly
used probiotics in the treatment of infectious diseases, includ-
ing antibiotic-associated and travellers’ diarrhoeas. Other
micro-organisms, including Saccharomyces boulardii), Strepto-
coccus thermophilus, Enterococcus faecium, Leuconostoc spe-
cies, Escherichia coli Nissle 1917 strain and Bacillus species,
are being researched in vitro or in animals and human trials,
or are being used in humans for prophylaxis or therapeutic
purposes [10, 13–15].
Specific criteria have been set for micro-organisms to qualify
as effective probiotics. These include adherence to host cells in
the gastrointestinal tract (GIT), ability to exclude or reduce
the adherence of pathogens to the GIT, stimulation of immu-
nity and the ability to persist and multiply in the GIT (resis-
tance to acidic gastric juice, basic pancreatic juice, lysozyme
and bile salts). Furthermore, other criteria include the ability
to produce acids, hydrogen peroxide and bacteriocins that are
antagonistic to the growth of pathogens and the ability to co-
aggregate to form a normal sustaining flora. They must pos-
sess some of these properties to qualify as probiotics.
Moreover, probiotic micro-organisms should be non-invasive,
non-carcinogenic and non-pathogenic [12, 16, 17].
The objective of this paper is to provide a critical review of
Salmonella infections and current treatment of salmonello-
sis, and to understand the prophylactic and therapeutic
potential of probiotic micro-organisms and their mecha-
nisms of action in preventing and treating Salmonella and
other enteric pathogens infections. In particular, this paper
focuses on probiotic yeasts, although probiotic bacteria are
also briefly discussed.
SALMONELLA: THE BACKGROUND
Salmonella is a genus of the family Enterobacteriaceae. It is
a Gram-negative, non-spore-forming, rod-shaped and fac-
ultative anaerobic bacterium. Salmonella cells move by
means of a peritrichous flagellum. They are 2–5 µm long by
0.5–1.5 µm wide and, depending on the serotype, the Salmo-
nella genome ranges from 4460 to 4857 kb. The bacterium
was first identified in a veterinary laboratory in the 19th
century in the USA. Salmonella is a lactose fermenter (some
sub-species) and a hydrogen sulfite producer, and is oxi-
dase-negative and catalase-positive. It hydrolyzes urea, uti-
lizes citrate and decarboxylates lysine as its sole carbon
source [5, 7].
The genus is classified into two species: Salmonella enterica
and Salmonella bongori. Biochemical and genomic analysis
of Salmonella enterica has led to further classification into
subspecies, including enterica, salamae, arizonae, diarizo-
nae, houtenae and indica [7, 18, 19]. The clinically import-
ant Salmonella species are classified under Salmonella
enterica, which is further classified into more than 2,579
serovars on the basis of their antigenicity [7, 20].
Salmonella species are harboured in the intestinal tract of
humans and farm animals. Reptiles and insects also act as
Salmonella reservoirs. Moreover, eggs, poultry meat, pork,
beef, dairy products, nuts, vegetables and water act as sour-
ces of Salmonella. The risk of infection is high in low- and
middle-income countries or societies, with more than 100
infections per 100 000 people per year [6, 7, 21, 22]. Some
Salmonella serotypes are host-specific, while others can
infect more than one type of warm-blooded animal [5]. The
S. Typhi and Salmonella enterica serovar Gallinarum sero-
vars are restricted to human and poultry hosts, respectively,
whereas Salmonella enterica serotype Dublin (S. Dublin)
and Salmonella enterica serovar Choleraesus are adapted to
cattle and pigs, respectively, but can infect other warm-
blooded animals. However, other serovars, such as Salmo-
nella enterica serovar Typhimurium (S. Typhimurium) and
Salmonella enterica serovar Enteritidis (S. Enteritidis), are
generalists and are able to infect any warm-blooded
animal [5].
The bacterium can be transmitted through faecal–oral
routes, where susceptible hosts may acquire Salmonella
through contaminated foods and water and therefore trans-
missions can be controlled through foods and water [6].
Moreover, infection with Salmonella from food or water can
also be prevented with vaccination. Salmonella vaccines
include killed whole-cell, Vi, live oral Ty2la and Vi-rEPA.
The use of vaccine may reduce infections, but availability,
efficacy, safety and cost are some of the issues that hamper
its use and effectiveness [22, 23].
SALMONELLA PATHOGENESIS
After the ingestion of contaminated food or water, Salmo-
nella colonizes the distal ileum and proximal colon [24, 25].
The infective dose for salmonellosis that is capable of estab-
lishing infection in the mucosa of the small intestine ranges
from 105 to 106 cells [26]. Salmonella uses its flagella as a
mode of movement as well as chemotaxis to target cells, the
enterocytes. In humans, Salmonella cells use type I fimbriae,
including long polar fimbriae (Lpf) and thin aggregative
fimbriae (Tafi), to adhere to enterocytes. Type IV pili are
Gut et al., Microbiology 2018;164:1327–1344
1328
Downloaded from www.microbiologyresearch.org by
IP:  140.159.2.227
On: Wed, 27 Feb 2019 04:22:55
used by S. Typhi to attach to host cells [27]. Once Salmo-
nella has adhered to the host cells on the apical side of M
cells or enterocytes, it uses Salmonella pathogenicity islands
(SPIs) – encoded type III secretion systems (T3SSs) – to be
phagocytized into the receptive macrophages [27]. Salmo-
nella cells can then be exocytosed into the interstitial spaces
of the lamina propria, where they are randomly picked by
macrophages, dendritic cells and polymorphonuclear cells
and distributed to the host efferent lymph in the mesenteric
lymph nodes before being transported to the spleen and
liver via the bloodstream [28]. The attachment of Salmo-
nella to the receptive epithelial cells and internalization into
lamina propria causes inflammatory responses, including
the release of pro-inflammatory cytokines. Pro-inflamma-
tory cytokines cause acute inflammatory responses which
lead to diarrhoea, ulceration and the destruction of the
mucosa cells [29].
Apart from the invasiveness of Salmonella cells, enterotoxin
and cytotoxin have been identified across all of the Salmo-
nella sub-species. These toxins are reported to be similar to
cholera toxins. Some of them have been found to be either
heat-labile or heat-stable, and they have been reported to be
associated with diarrhoea [30–32]. Enterotoxin was
reported to induce the accumulation of fluid in the ligated
murine ileal loop and was also found to have cytotoxic
activity [33]. Cytotoxin inhibits protein synthesis, and it has
been reported that it is responsible for intestinal mucosal
surface damage, as well as enteric symptoms and inflamma-
tory diarrhoea [25]. S. Typhi toxin is reported to be associ-
ated with persistent infection and the signs and symptoms
of typhoid fever [34]. On the other hand, another study
reported that there were no differences in virulence between
mutant Salmonella without toxin phenotypes and wild-type
with toxin phenotypes [35].
O antigen lipopolysaccharide (LPS) plays a role in the path-
ogenesis of Salmonella infections. All parts of LPS are
important in the pathogenesis of Salmonella, but the length,
structure, composition and surface roughness of O side-
chains can influence the virulence. Failure to produce a full
length of chain decreases virulence. The length of the chain
influences resistance to the lytic action of the complement
cascade. Furthermore, smooth surface strains are more
resistant to the lytic action of the cascade than rough surface
strains, and this has been postulated to be due to steric hin-
drance of complement cascade binding to the Salmonella
cell [25].
Salmonella pathogenesis is also influenced by the virulence
plasmids, which contain virulence genes. S. Typhimurium,
S. Dublin and S. Enteritidis virulence plasmids have been
reported to be responsible for systemic dissemination of
infection in the mesenteric lymph nodes, spleen and liver. It
has been reported that virulence plasmids are commonly
found in Salmonella isolated from human or animal organs
or blood, rather than in faeces, food, or environmental
samples [25].
Salmonella also possesses other virulence factors (including
flagella and flagellin), superoxide dismutase and ion acquisi-
tion systems [36]. Flagella increase invasiveness due to the
motility of Salmonella, while flagellin has been reported to
induce an inflammatory response. Bactericidal reactive oxy-
gen species that have been produced against intracellular
pathogens by the host can be inactivated by Salmonella
superoxide dismutase. Moreover, Salmonella produces ion
acquisition systems for the acquisition or transport of iron,
magnesium, zinc and potassium, where their concentrations
are low. Salmonella produces siderophores, including enter-
obactin and salmochelin. These siderophores are critical in
accessing limited iron in the host. Salmonella also uses
CorA, MgtA and MgtB systems to acquire limited magne-
sium. ZnuABC and Trk systems are used for zinc and potas-
sium uptake, respectively. All of these ions are critical for
the survival and pathogenesis of Salmonella [36].
DISEASES CAUSED BY SALMONELLA
INFECTIONS
Infection of humans with Salmonella results in three main
infectious diseases, namely typhoid fever, paratyphoid fever
and NTS. Typhoid and paratyphoid fevers are caused by
S. Typhi and Salmonella enterica serovar Paratyphi (S. Para-
typhi), respectively, and are characterized by gastroenteritis
and complications such as septicaemia, immunological
symptoms, leukopenia and neurological sympotoms. These
typhoidal and paratyphoidal complications account for
deaths [7, 34]. On the other hand, S. Typhimurium, S.
Enteritidis, Salmonella enterica serovar Newport (S. New-
port) and Salmonella enterica serovar Heidelberg (S. Heidel-
berg) cause NTS infections, which are restricted to
gastroenteritis (nausea, vomiting and diarrhoea) or occa-
sional bacteraemia (dissemination of infection in the body),
and are usually non-fatal [7].
LABORATORY DIAGNOSIS OF SALMONELLA
INFECTION
Blood culture is the gold standard method for diagnosis of
S. Typhi and Salmonella Paratyphi infections [37]. Blood
volume, duration of illness, the presence of bacteraemia and
antibiotic treatment commencement can impact on the reli-
ability of the result obtained from blood culture [23].
Salmonella is serologically classified into six serotypes,
which are detected on the basis of their antigenicity. The
Widal test method, which detects the presence of Salmonella
O and H antigens, is another method that can be used to
diagnose Salmonella infections and is useful in areas where
resources are limited. This method does not differentiate
Salmonella species or serotypes and can cross-agglutinate
with other non-Salmonella Enterobacteriaceae bacteria.
False-negative Widal tests have been reported and false-pos-
itive results may also be expected in patients with malaria,
dengue and disseminated tuberculosis [23]. The enzyme-
linked immunosorbent assay (ELISA), which detects IgM
and IgG antibodies against Salmonella surface molecules, is
Gut et al., Microbiology 2018;164:1327–1344
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another useful tool in the diagnosis of Salmonella infection.
The Typhidot ELISA kit detects both IgG and IgM. Its sensi-
tivity and specificity have been reported as >95%, and 75%,
respectively. Typhidot-M, which only detects IgM, has a
sensitivity of 90% and a specificity of 93% [23].
Validated molecular biology methods are also employed in
the diagnosis of Salmonella infections from blood, faeces,
foods and environmental samples [25]. The nested multi-
plex polymerase chain reaction method (PCR), which
targets the Salmonella flagellin gene (fliC), polysaccharide
capsule gene and virulence (vi) genes (tviA and tviB), is
reported to offer better specificity, sensitivity and turn-
around times compared to the other methods
discussed [38].
TREATMENT OF SALMONELLA INFECTIONS
BY ANTIBIOTIC DRUGS
Antibiotic drugs are critical in the treatment of infectious
diseases and have considerably improved quality of life, in
addition to reducing the mortality associated with bacterial
infections. The selectivity of antibiotic drugs against invad-
ing bacteria ensures minimal harm to the patients and at
the same time guarantees maximum eradication of the tar-
get bacteria [10].
NTS infections do not usually require treatment with antibi-
otic drugs, however complications such as meningitis and
septicaemia do occur and require treatment with antibiotic
drugs, including ciprofloxacin, ceftriaxone and ampicillin
[22, 39]. Infections caused by S. Typhi and S. Paratyphi may
involve serious complications and require treatment with
antibiotics such as cefixime, chloramphenicol, amoxicillin,
trimethoprim/sulfamethoxazole (TMP-SMX), azithromy-
cin, aztreonam, cefotaxime or ceftriaxone to prevent death
[23]. Dexamethasone is a corticosteroid drug and may be
used when a complication such as delirium, obtundation,
stupor, coma or shock occurs [23].
CURRENT ISSUES WITH THE USE OF
ANTIBIOTIC DRUGS FOR TREATING
SALMONELLA INFECTIONS
Bacterial infections have traditionally been treated with
antibiotic drugs; however, certain bacterial species have
developed resistance to current antibiotics. Bacteria with the
ability to grow or survive in a concentration of antibiotic
drug that is normally sufficient to be bactericidal or bacteri-
ostatic are referred to as antibiotic drug-resistant bacteria,
whereas antibiotic-susceptible bacteria are species that can
be killed or have their growth inhibited by the recom-
mended dose of antibiotic drug [40]. Resistance to an anti-
biotic drug may be innate or acquired through exposure of
the bacteria to the antibiotic drug. Conjugation, transduc-
tion and transformation are the genetic mechanisms used
by bacteria to acquire antibiotic-resistant genes. Conjuga-
tion involves the transfer of DNA on plasmids from one
organism to another. In transformation, naked DNA is
carried directly from one organism to another, while in
transduction, the DNA is transferred by bacteriophage [40].
There is emerging resistance among Salmonella species to
first-line antibiotic drugs, as well as to alternative medicines
[21]. It was reported in Malawi in 2010 that 7% of S. Typhi
infection cases were multi-drug resistant, and in 2014 the
figure increased to 97% [41, 42]. In the USA, S. Enteritidis
accounted for 50% of ciprofloxacin-resistant infections,
whereas S. Newport, S. Typhimurium and S. Heidelberg
were reported to be responsible for 75% of antibiotic-resis-
tant infections, due to their resistance to ceftriaxone and
ampicillin. The resistance of Salmonella species to antibiotic
drugs has been shown to be serotype-specific according to
metadata research [39].
The rise of antibiotic-resistance among pathogenic bacter-
ia, including Salmonella, species is associated with a num-
ber of factors, including excessive use of antibiotic drugs as
a result of easy access (over the counter and internet sales)
in some countries [39]. The use of antibiotics for growth
promotion in animal husbandry and for the protection of
crops, together with poor hygiene practices, have also con-
tributed to the overuse of antibiotic drugs, and hence resis-
tance [10, 39, 40].
The inability to treat infectious bacterial diseases has
resulted in high mortality and morbidity and substantial
economic losses. It has been reported that in Europe, 25 000
people die and e1.5 billion is spent annually due to antibi-
otic-resistant infections, whereas in the USA, 23 000 deaths
are reported and >$20 billion is spent on nosocomial antibi-
otic-resistant infections in hospitals in a year [40].
The effect of antibiotic drugs on the human microbiome is
of great significance. Antibiotic drug use has been associated
with interference with the normal flora, and as a conse-
quence, disorders such as inflammatory bowel disease or
allergies may happen due to the altered microbiome [10].
Furthermore, antibiotic-associated diarrhoea (AAD) is
caused by changes to the microbiome resulting from the
administration of antibiotics. This reduces carbohydrate
digestion and short-chain fatty acid absorption and thus
results in induced osmotic diarrhoea. Long hospital stay due
to AAD contributes to the risk of nosocomial infections and
is an increased economic cost [10].
PREVENTION AND ALTERNATIVE/
COMPLEMENTARY TREATMENTS OF
SALMONELLA INFECTION BY PROBIOTICS
Probiotic micro-organisms exert their prophylactic and
therapeutic properties against pathogenic micro-organisms
in three main ways: they may modulate both innate and
acquired immunity, act directly on the pathogens and pro-
duce antibiotic molecules [43]. These mechanisms of action
are influenced by the probiotics metabolism, the cell surface
molecules, the ability to secrete antibacterial molecules and
the genetic makeup of the organisms [43].
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Probiotic bacteria such as Lactobacilli, Enterococci, Bifido-
bacteria, Pediococcus, E.coli, Streptococcus and Leuconostoc
species are normally found in the human GIT, where they
form normal flora [44], and are commonly included in pop-
ular fermented functional foods to make their delivery easy
[44–47]. Probiotic products can also be in the form of
lyophilized capsules or powders or aqueous solutions [48].
Probiotic bacteria have been widely used in the treatment of
infectious bacterial diseases and their efficacious application
are summarized in Table 1. Apart from the treatment of
infectious diseases briefly discussed below, these organisms
confer other benefits, such as appropriate digestion, epithe-
lial cell function, metabolism, enteric nerve function and
angiogenesis to the host [10].
PROPHYLACTIC AND THERAPEUTIC
EFFICACIES OF YEASTS
Yeasts are eukaryotes and are classified into two groups:
ascomycetes and basidiomycetes [49, 50]. The ascomycetes
division contains yeast species with probiotic potential, such
as the genera Saccharomyces, Schizosaccharomyces, Kluvero-
myces, Zygosaccharomyces and Devaryomyces [49].
Studies have indicated that yeast can be used in the preven-
tion and treatment of infectious bacterial diseases, including
typhoid, paratyphoid and NTS. Currently, S. boulardii is the
yeast strain being used as a probiotic [51–53], while other
yeast species and strains have been proven to be efficacious
in in vitro and animal trials [54]. In contrast to probiotic
bacteria, which are affected by drugs that target enteric
pathogenic bacteria, yeasts are not targeted when they are
used as a complementary therapy [48]. Fig. 1 summarizes
the antagonistic mechanisms of probiotics against bacterial
pathogens. These mechanistic properties of probiotic yeasts
against pathogens are discussed below and further studies
are summarized in Table 2. Yeasts also have a wide range of
other beneficial applications for humans, as illustrated in
Fig. 2.
PROTECTION AND PRESERVATION OF TIGHT
JUNCTIONS
Tight junctions are the apical epithelial layers that separate
the interface lumen of the GIT and deep cell layers. It is
composed of transmembrane proteins, cytoplasmic adap-
tors and the actin cytoskeleton. Tight junctions attach adja-
cent cells to each other and provide intercellular seals. They
function as a physical barrier that prevents noxious objects,
including pathogenic organisms, from entering into deeper
layers within tissues. However, some micro-organisms, such
as Salmonella species, have developed mechanisms to evade
this barrier [55]. Probiotic micro-organisms, including yeast
species, have been reported to not only maintain normal
functions of the gut mucosa, but also protect it from toxins,
allergens and pathogens. The protective effects of probiotics
are attributed to cytoprotection, cell proliferation, cell
migration, resistance to apoptosis, synthesis of proteins and
gene expression [56]. S. boulardii is reported to inhibit pro-
inflammatory cytokines such as IL-8 production by the host
and prevent the activation of MAP kinases Erk1 /2 and
JNK/ SAPK. S. boulardii anti-inflammatory factor (SAIF)
was postulated to be responsible for tight junction protec-
tion and preservation. Furthermore, S. boulardii produce
produces proteases that break down toxins produced by
bacterial pathogens [57].
Inflammatory bowel diseases such as irritable bowel syn-
drome, gluten intolerance, gastroenteritis and H. pylori
infections disrupt tight junctions and this can predispose
the susceptible host to Salmonella and other enteric patho-
gen infections [56]. Mice with genetic and inducible colitis
(hence disrupted tight junctions) were more prone to be col-
onized and infected by S. Typhimurium than mice without
inflammatory diseases [58]. These inflammatory diseases
are currently prevented and/or treated using Saccharomyces
species [56] and this shows how yeasts may be used prophy-
lactically in infection prevention with respect to entero-
pathogenic bacteria such as Salmonella. The infection rate
was reduced in the yeast-treated group due to the protection
of tight junctions through cytoprotection, cell proliferation,
cell migration, resistance to apoptosis, synthesis of proteins
and gene expression.
IMMUNOMODULATORY PROPERTIES
The immunomodulatory properties of probiotics are associ-
ated with their cell wall components, DNA and metabolites,
and therefore their ability to elicit immunity may be inde-
pendent of the viability of probiotics such as yeast cells [43].
The target host cells for immunomodulation by probiotics
are enterocytes and gastrointestinal-associated immune
cells. The sensitive cells can be stimulated due to the pres-
ence of b-glucan and mannose receptors for probiotic frag-
ments or whole cells. The adhesion of probiotic organisms
to sensitive cells or the production and release of soluble
factors may modulate immunity or trigger signalling cas-
cades in immune cells [43]. Yeast cell wall components,
including mannoproteins and b-glucan, induce immuno-
modulatory responses when they interact with dentritic or
other immune cells with receptors [59]. For example, the
attachment of S. boulardii to dendritic cells (DCs) was
reported to induce the secretion of immunoglobulins A and
M and cytokines, including interleukin (IL) 1b, IL-12, IL-
6, TNFa and IL-10. This immunomodulatory mechanisms
was postulated to be due to tumour necrosis factor alpha
(TNFa) and the transcriptional upregulation of C–C che-
mokine receptor type 7 mRNAs by yeast cells [60].
The cell wall components of Saccharomyces cerevisiae,
including mannoprotein, act as nonspecific immune stimu-
lators by interacting with macrophages through receptors.
Yeast cell components, including b-glucan and mannopro-
tein, have adjuvant effects and can activate neutrophils,
eosinophils, macrophages and complements [61].
The immunomodulatory properties of pathogenic fungal
species are postulated to be due to the presence of b-glucan
receptors on a susceptible host [62]. Beta-glucan is also
Gut et al., Microbiology 2018;164:1327–1344
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Table 1. Prophylactic and therapeutic properties of probiotic bacteria
Probiotic micro-organisms Indicator enteric pathogens and/
or animal models
Treatment mechanisms and outcomes References
L.casei 11578, Lactobacillus delbrueckii
ssp. bulgaricus 11 842 (L. bulgaricus),
Lactlbacillus fermentum 1493
(L. fermentum) and the commercial
probiotic product, PROB
Infection of neonatal broiler chicks
with S. Enteritidis
Significant reduction of S. Enteritidis in the chick faeces in a time-
dependent manner; feeding 24 h prior to infection was
efficacious
[111]
L. casei, L. bulgaricus, Lactobacillus
cellobiosus (L. cellobiosus),
Lactobacillus helveticus (L. helvetticus)
and L. fermentum
Infection of 1-day-old broiler chicks
with S. Enteritidis
Reduced colonization of chicks’ gastrointestinal tract [112–114]
L. casei, L. bulgaricus, L. cellobiosus,
L. helveticus and L. fermentum
Infection of neonatal broiler chicks
with S. Enteritidis and S.
Typhimurium
Caecal tonsils load of S. Enteritidis was reduced by 60–70%, while
the S. Typhimurium load in caecal tonsil was reduced by 89–
95% as a result of treatment with probiotic compared to control
[115]
Commercial probiotic – floraMax Infection of chicks and poults with
S. Heidelberg
Reduced colonization and hence lower recovery of S. Heidelberg
from caecal tonsil from both treated chicks and poults compared
to control chicks and poults
[116]
Lactobacillus rhamnosus (L. rhamnosus)
GG (ATCC 53103) and B. longum 46
(DSM14583)
V. cholerae Removed 68 and 59% enterotoxin in an aqueous solution,
respectively
[117]
Bifidobacterium longum subsp. longum/
infantis
E.coli 0157: H7 Prevented the production of toxin in the caecum and translocation
of toxin from the GIT to the blood stream and hence reduced
mortality
[118]
Lactobacilli, Bifidobacterium bifidum
strains Bb12 and Lactobacillus kefir
S. Typhimurium Secrete molecules that prevent invasion of epithelial cells [43]
Lactobacillus acidophilus (L.acidophilus) In vitro trial using human colonic
adenocarcinoma cell line infected
with S. Typhimurium
Attenuation of inflammatory response triggered by S.
Typhimurium infection
[119]
E.coli Nissle 1917 Stimulation of intestinal epithelial
cell line
Suppression of TNF-a induced IL-8 transcription and production
Only viable E.coli Nissle 1917 showed immunomodulation
[120]
L. fermentum ME-3 and ofloxacin
antibiotic, L. plantarum cell-free
extract with co-trimoxazole
S. Typhimurium Prevented invasion of organs and completely eradicated S.
Typhimurium
[121, 122]
E.coli Nissle 1917 (EcN) Infection of Caco-2 cells with C.
perfringens
IL-1 b, IL-6, G-CSF and GM-CSF production was significantly
increased in the absence of EcN, but decreased in the presence of
EcN
[123]
Lactobacillus rhamnosus G and
Bifidobacterium lactis Bb12.
E. coli and S. Typhimurium in vitro
experiment
Significant co-aggregation of pathogens with probiotic bacteria [124]
E.coli Nissle 1917 and L. acidophilus E.coli 0157:H7 and cell lines Suppressed production of pro-inflammatory cytokines and
inhibited E.coli 0157:H7 virulence
[125]
E.coli Nissle 1917 S. Typhimurium, Yersinia
enterocolitica, Shigella flexneri,
Legionella pneumophila and
Listeria monocytogenes
The ability of these probiotic bacteria to inhibit invasion is not
dependent on direct contact with the pathogen; rather it is due to
the production of not-yet-identified molecules
[126]
Bifidobacterium longum Bar33 and
B. lactis Bar30
Infection of Caco-2 cells with S.
Typhimurium and E. coli H10407
Displaced pathogenic bacteria from attachment site of CaCo-2 [127]
E.coli Nissle 1917 C. difficile and C. perfringens Inhibited production of and deactivated toxins [123]
L. plantarum 299 v, L. rhamnosus GG,
Bifidobacterium lactis Bb12 and L.
rhamnosus LGG
Infection of human mucusa cells
with enteropathogenic E. coli, S.
Typhimurium ATCC 12028 and
Clostridium histolyticum DSM
627
Competition for the same receptor in the GIT and stimulation of
mucin production by probiotic resulted in inhibition of
pathogenic bacteria adhesion to the GIT; probiotics also degrade
carbohydrate receptors for pathogens, exclude pathogens by
establishing biofilms, produce receptor analogue for pathogens to
bind to instead of binding to host cells and prevent binding of
pathogens by producing surfactants
[43, 128]
Genetically engineered L. lactis C. difficile and H. pylori in mice Elicited immunity by expressing non-toxic fragments of TcdA and
TcdB and produced H. pylori lipoprotein Lpp20, which elicited
immunity in vivo and therefore prevented or treated H. pylori
infections
[129]
Single-strain Lactobacillus species E. coli, Enterococci faecalis,
Enterococcus faecium,
Enterpbacter cloacae,
Streptococcus salivarius, Listeria
monocytogenes, S. aureus, Proteus
mirabilis, P. aeruginosa and
Bacteroides thetaiotaomicron in in
Inhibited growth due to antibacterial metabolites other than
hydrogen peroxide because of inhibition in anaerobic condition
[130]
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found in probiotic yeast species such as S. cerevisiae (in the
cell wall) and therefore a non-pathogenic yeast species may
have the potential to modulate cell-mediated and humoral
immunity in a host with its receptors [60].
Among the host receptors that recognize b-glucan are com-
plement receptor 3 (CR3), dectin-1, scavenger receptor class
F member 1 (SCARF1), cluster of differentiation 36 (CD36)
and cell death abnormality protein 1 (CED1) [which is
found in nematodes and is similar to human scavenger
receptor from endothelial cells (SREC)] [62, 63]. CR3 is an
integrin dimer and is expressed by immune cells such as
monocytes, macrophages, DCs, neutrophils and natural
killer cells. Dectin-1 is primarily expressed by macrophages,
dendritic cells and neutrophils, while SCARF1 is expressed
on macrophages. The binding of stimulators such as b-glu-
can to the above receptors on immune cells elicits immune
responses. Some of these immune responses have been
found to include phagocytosis, oxidative burst, neutrophil
degranulation, fungal killing and the production of inflam-
matory lipid mediators, cytokines and chemokines. Chemo-
kines recruit and coordinate the activation of other immune
cells, including T cells, B cells and natural killer cells [60,
62]. CD36 is a sensor for b-amyloid, modified low-density
lipoprotein, bacterial diacylated lipoproteins and lipotei-
choic acid. These receptors mediate the binding of Candida
albicans and Cryptococcus neoformans to mammalian cells
via b-glucan and induce inflammatory cytokines and
chemokines. However, collaboration with Toll-like receptor
2 (TLR2) is needed in order for these receptors to induce
immune responses [62].
Mannose receptor is expressed by activated macrophages.
Mannose is also recognized by langerin and dectin-2 and
these also act as its receptors. Stimulation of mannose recep-
tors can lead to pro-inflammatory or anti-inflammatory
responses. Langerin (also known as cluster of differentiation
207) is a receptor on Langerhans cells, whereas dectin 2 is a
receptor for mannan on a fungal cell wall. The type of
response is dependent on the yeast cell wall components
(the presence of b-glucan and mannoproteins) and the host
cell receptors. Additionally, dectin 2 has an affinity for a-
glucan, while langerin has an affinity for chitin [64].
The immunomodulatory properties of yeasts was demon-
strated in S. boulardii, which has strong immunomodula-
tory properties; it induced the production of
immunoglobulin A (IgA), tumour necrosis factor-alpha
(TNF-a) and many ILs, including IL-1b, IL-5, IL-6, IL-10
and IL-12, as well as downregulating the production of IL-8
expression by acting on the NF-kB (nuclear factor kappa-
light-chain-enhancer of activated B cells) pathway in unin-
fected enterocytes and on mitogen-activated protein kinases
(MAPKs) and AP-1activator protein-1 (AP-1) in S. Typhi-
murium-infected enterocytes [54, 65]. S. boulardii was
shown to reduce the production of pro-inflammatory
Table 1. cont.
Probiotic micro-organisms Indicator enteric pathogens and/
or animal models
Treatment mechanisms and outcomes References
vitro experiment
Bifidobacterium breve (B. breve) strain
Yakult
E. coli (STEC) O157: H7 in mouse
model
B. breve inhibited stx gene production by STEC cells [131]
Clostridium butyricum strain MIYAIRI Enteropathogenic E.coli (EHEC)
0157: H7 in mouse model
Inhibited toxin expression by producing butyric and lactic acid and
reduced viability of EHEC E.coli 0157: H7 by producing butyric
acid
[132]
Lactobacillus strains, three Pediococcus
strains and four Bifidobacterium
strains
E.coli (EHEC) 0157: H7 in in vitro
experiment
All probiotics inhibit toxin production due to the production of
organic acid, which resulted in low pH
[133]
Bifidobacterium thermophilum RBL67 Human colonic fermentation model
using HT29-MTX cell lines;
infection with Salmonella and in
vitro trial
Probiotic prevented invasion and protected epithelial lining;
probiotic also prevented expression of virulence factors by
Salmonella
[134, 135]
Feed-grade lactobacilli (TGI) Poultry (broiler) infection with
Salmonella
Consumption of probiotic increased liveability in Salmonella-
infected broilers compare to the control
[136]
L. plantarum MTCC5690 An animal trial using mice infected
with Salmonella
Consumption of probiotic in fermented milk stimulated immunity
and prevented GIT colonization by Salmonella and hence
prevented infection
[137]
L. salivarius 59 and Enterococci faecium
PXN33
An animal trial using poultry
infected with Salmonella
Prevented colonization of Git by S. Enteritidis when used as multi-
strain probiotic
[138]
L. rhamnosus GG (2109 organisms per
day)
A human trial involving 400 adult
travellers
Reduced traveller’s diarrhoea to 3.9% in the treatment group
compared to 7.4% in the placebo group
[139]
Genetically engineered E. coli Nissle
1917
Animal trial using turkey infected
with Salmonella
Ninety-seven per cent lower carriage of Salmonella in the GIT in
the treated group compared to the control group, postulated to
be due to the production of antimicrobial molecules by E. coli
Nissle 1917
[140]
Genetically modified non-pathogenic
S. Typhimurium
S. Typhimurium and murine model Protected murine model due to competition for nutrients with
pathogenic strains
[141]
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immune factors, including IL-6 and TNF-a, in a pathogenic
E. coli infection colitis and it prevented E. coli-mediated
apoptosis of T84 colonic cell lines [54]. In contrast to the
above findings, the ability of S. boulardii to modulate immu-
nity in healthy mucosa was reported to be minimal in
research conducted on a murine model [59].
Yeast genera (including Saccharomyces, Kluyveromyces and
Issatchenkia) isolated from kefir milk showed downward
regulation of intestinal epithelial innate immune responses
when cells were subjected to TLR ligands such as Salmo-
nella flagellin and E. coli LPS. Kluyveromyces marxianus
inhibited the expression of TNF-a and IL-1b cytokines by
enterocytes when stimulated by LPS and flagellin. This
yeast strain was also shown to block the NF-kB pathway
and therefore inhibited pro-inflammatory cytokines, che-
mokines and the release of TNFa. The immunomodulatory
ability of yeast species (especially S. cerevisiae CIDCA8112
and Kluyveromyces marxianus) isolated from kefir was
shown to be dose-dependent. The viability of yeast cells was
found to be a deciding factor in the downregulation of the
innate response by human colonic epithelial cell lines
(Caco-2). The inactivation of yeast strains by heat and UV
irradiation completely destroyed the immunomodulatory
effects [66, 67].
BINDING OF PATHOGENIC BACTERIA ONTO
YEAST CELL WALLS
Cell adhesion is defined as a process whereby cells attach to
each other or to a foreign surface with the aid of adhesins.
In this context, foreign surfaces may include other biotic or
abiotic structures [68]. In yeasts, adhesins are protein
mosaics on the surface of cell walls which are involved in
development, symbiosis and pathogenesis [69]. Currently,
eight S. cerevisiae adhesins have been identified and these
include FLO1, FLO5, FLO9, FLO10, FLO11 (or MUC1),
FIG2, LgFLO1 and AGA1. The expression of these adhesins
is determined by genetic factors, such as yeast species or
environmental growth conditions, including growth
medium, aeration or acidity [68, 69].
Fig. 1. Antagonistic mechanisms of probiotics against pathogenic bacteria [3, 52, 54, 70, 74, 86, 89, 92].
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Using S. cerevisiae as a model, yeast cells have been found to
form six different communal structures. Sessile non-adhe-
sive cells that do not produce adhesins on a solid surface
exposed to air can form non-adhesive colonies, especially
on laboratory agar media. However, in a liquid medium,
non-adhesive yeast cells exist as individual cells in a plank-
tonic form that makes the media look turbid. Yeast cells can
produce self-adhesion genes and therefore auto-aggregate
without aggregating to foreign biotic or abiotic surfaces.
Alternatively, yeast cells can produce adhesins for self-
aggregation as well as an adherent to foreign surfaces and
thereby form a biofilm. Furthermore, adhesin-producing
yeast cells in liquid media can form flocs on the bottom or
flor on the surface. Lastly, yeast cells can develop filaments
when they produce adhesins and adhere to the bottom in
liquid substrates [68].
Intimate binding of S. Typhimurium pili to yeast S. boular-
dii has been demonstrated by transmission electron
microscopy [70]. The underlying mechanism of binding is
postulated to be due to the presence of mannose-specific
Table 2. Prophylactic and therapeutic properties of yeasts
Probiotic micro-organisms Indicator enteric pathogens and/
or animal models
Treatment mechanisms and outcomes References
S. boulardii Human trials Improved tolerance to number of calories per day, reduced
incidence of diarrhoea, reduced number of treatment days and
reduced duration of diarrhoea
[74]
S. boulardii Salmonella and E.coli in rat model Neutralized LPS and therefore reduced its toxicity in the rat model;
inflammatory lesions and necrotic bodies were seen in the
control’s liver and heart
[98]
S. cerevisiae UFMG A-905 from
Brazilian distilled spirit cachaça,
S. cerevisiae 982 from cheese and
S. boulardii from chicken faeces
PBMCs (peripheral blood
mononuclear cells) and mouse
model
Reduction of inflammation and IL-6, TNF-a, interferon gamma
(IFN-g) and IL-10 by S. cerevisiae UFMG A-905 production, and
stimulation of type 1 T helper (th1) response by S. cerevisiae 982
Induced TNF-a and IL-10 production
Reduced the serum level of IL-6 in a mouse colitis model.
Immunomodulatory properties through reduction of
inflammation and IL-6, TNF-a, Interferon gamma (IFN- g) and
IL-10 production
[54]
S. cerevisiae Salmonella species in in vitro
experiment
Viable yeast bind better to Salmonella than non-viable yeast [71]
Pichia kudriavzevii RY55 E. coli, Enterococcus faecalis,
Klebsiella sp., S. aureus,
Pseudomonas aeruginosa and
Pseudomonas alcaligenes in in
vitro experiment
Mycoccins inhibited the growth of pathogenic bacteria [86]
Candida krusei isolated from fermented
vegetables
E. coli, S. Typhimurium, S. aureus
and Bacillus cereus in in vitro
experiment
The killer toxin produced by yeast inhibited the growth of
pathogenic bacteria
[88]
Yarrowia lipolytica Bacterial species in in vitro
experiment
Produces organic acids, including a-ketoglutaric, a pyruvic, citric
and isocitric acid, which may have bactericidal or bacteriostatic
effects on bacterial growth
[142]
S. cerevisiae In vitro experiment on
Enterobacteriaceae and lactic acid
bacteria
Bactericidal or bacteriostatic effects due to production of carbon
dioxide, sulfur dioxide, a high concentration of ethanol and
secretion of organic acids which in turn reduce pH
[142, 143]
S. boulardii V. cholerae, C. difficile and C.
perfringens toxins in mouse
model
Minimized the effects of toxin fluid secretion, and decreased
mucosal permeability, mucosal damage and the release of
inflammatory cytokines when administered to mice before they
they were given the cholera toxin, and deactivated or inhibited
production of toxins by C. difficile and C. perfringens
[74]
S. cerevisiae and C. albicans Pseudomonas, Staphylococcus
epidermidis and Burkholderia
pseudomallei in in vitro
experiment
Quorum-sensing molecules (farnesol) prevented biofilm formation
by Pseudomonas and Staphylococcus epidermidis and enhanced
the efficacy of B-lactams against Burkholderia pseudomallei
[3, 100]
S. boulardii Human trial in children Decreased severity and duration of infectious diarrhoea in children
and shortened acute diarrhoea by almost a day in a clinical trial
[10]
S. cerevisiae IFST062013 isolated from
fruit juice
In vitro experiment on Gram-
negative and -positive bacteria
Significant antibacterial effects in gram-negative than gram-
positive bacteria compared to antibiotic doxycycline, while cell
lysate was more potent than whole cells or supernatants; induced
pro- and anti-inflammatory mediators simultaneously and as a
result enhanced the maintenance of balance between Th1- and
Th2-type cytokines
[89]
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adhesins/receptors such as fimbriae on bacteria cell
walls that can bind to mannose on yeast cell walls. S. bou-
lardii cell walls possess high mannose content and hence
the capacity to bind bacteria pathogens with mannose-
binding fimbriae [70, 71]. Bacterial pathogens, including
Salmonella species, have been reported to bind better to
probiotic yeasts than to parabiotic yeasts [71]. Moreover,
adhesions of pathogenic bacterial cells onto yeast cell walls
were found to be prominent when yeast growth was at the
stationary phase compared to other growth phases [72].
The presence of sugars (including mannose, glucose and
maltose media), and to some extent bile salts, in aqueous
solutions was found to inhibit the binding of S. boulardii
to pathogenic bacteria, including Salmonella species [70,
72]. Therefore, to improve the binding of S. boulardii to
pathogenic bacteria, the consumption of foods or drinks
rich in these sugars should be limited when yeast is used
prophylactically or therapeutically.
Some bacteria, including Salmonella species, do show varia-
tion in the expression of fimbriae and therefore specific
binding of yeast to the Salmonella may vary depending on
the strains and/or genetic mutations [73]. Consequently, the
efficacy of adhesion as a prophylaxis can be influenced by
strains or genetic mutations that may occur over time.
Enteropathogenic bacteria, including Salmonella species
and pathogenic E.coli, have been shown to preferentially
and irreversibly bind to surfaces of S. boulardii [52, 71, 72].
The binding of pathogenic bacteria onto yeast cell walls lim-
its their infectivity, since S. boulardii does not bind to the
GIT; the bound bacterial cells pass transiently through the
GIT and are excreted in the faeces [74].
The ability of S. boulardii to bind enteropathogenic bacteria
is independent of viability; both probiotic and para-probi-
otic yeasts were shown to bind pathogenic bacterial cells
[71, 75]. Interestingly, yeast species were reported not to
bind to bacteria normally found in GIT, with the exception
of the S. cerevisiae UFMG 905 strain, which bound Bacter-
oides fragilis [72]. S. boulardii has been reported to signifi-
cantly reduce the internalization of S. Typhimurium in a
human T84 cell monolayer when both yeast and the patho-
gen were applied together in an in vitro experiment [70].
Furthermore, Pichia pastoris X-33 and S. boulardii have
been reported to reduce the binding of S. Typhimurium to
human colorectal HCT-116 cells (by 47 and 37%, respec-
tively) [76].
Mice infected with S. Typhimurium showed colonization
along the GIT, but when the infected mice were adminis-
tered with S. boulardii, the bacterial cells clustered around
Fig. 2. Biotechnology applications of yeast [49].
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the yeast cells, which was indicative of the adherence of
S. Typhimurium onto S. boulardii cells [65].
GROWTH INHIBITION
The growth inhibitory properties of probiotics, especially
yeasts, against bacteria have been proposed to include the
production of a high concentration of ethanol, the synthesis
of killer toxins, pH changes, organic acid production and
competition for nutrients [77].
Competition for nutrients is considered to be the most
important antagonistic property of yeast against other fungi
in the context of postharvest fungal pathogens in fruits;
yeast species have the capacity to quickly deplete glucose,
fructose and sucrose, and therefore suppress the growth of
other micro-organisms [77]. Moreover, some yeast species
possess iron sequestering molecules that give them a com-
petitive advantage to deplete iron, which is needed for
growth and pathogenesis by many pathogens [77].
Killer toxins, also called mycocins, are extracellular proteins,
glycoproteins or glycolipids that are produced by yeast spe-
cies against other yeast species with receptors for the toxins.
The toxins genes are carried on extra-chromosome ele-
ments, including double-stranded RNA virus and double-
stranded linear DNA, or on a chromosome [77]. The toxins
kill susceptible yeasts but do not affect the producer. The
mechanism of action of killer toxins involves the inhibition
of beta-glucan synthesis or the hydrolysis of beta-glucan in
the cell wall of the target yeast, the inhibition of DNA syn-
thesis in the target yeast, the cleavage of tRNA, the inhibi-
tion of calcium uptake and the leakage of ions due to the
formation of channels on the cytoplasmic membrane [77].
Killer toxins are large glycoprotein molecules and conse-
quently have the potential to induce unwanted immune
responses in the host [78], and therefore further studies on
molecular size and possible modification are needed with
regard to antigenicity and toxicity before these toxins are
used therapeutically[79]. Several yeast genera, including
Saccharomyces, Candida, Cryptococcus, Debaryomyces,
Kluyveromyces, Pichia, Torulopsis, Williopsis and Zygosac-
charomyces, can produce killer toxins [77].
Yeast metabolites such as sulfur dioxide, carbon dioxide and
ethanol have been postulated to have antagonistic effects on
enteropathogenic bacteria. Sulfur dioxide, which can be pro-
duced by yeasts during fermentation, when dissolved in
aqueous medium, produces sulfuric acid, which lowers the
pH and therefore exerts its bactericidal or bacteriostatic
effect. Furthermore, sulfuric acid is postulated to block
microbial enzyme activity through the reduction of disulfide
linkage, resulting in an antagonistic property against micro-
organisms [80]. Moreover, the antibacterial property of car-
bon dioxide produced by yeast during fermentation is
attributed to its dissolution in aqueous solution, which low-
ers the pH [81, 82]. Ethanol, a product of yeast metabolism,
disrupts bacterial cell membranes through the denaturation
of proteins and the dissolution of lipids, subsequently caus-
ing the lysis of bacterial cells in an in vitro experiment [83].
Concentrations of carbon dioxide and ethanol that are bac-
tericidal may also be harmful to host cells. Ethanol has been
reported to affect red blood cells physically and biochemi-
cally. Ethanol-induced membrane fluidization, decreased
haemogloblin content and concentration in the cytoplasm
have been reported [84]. Furthermore, it has been reported
that ethanol has negative effects on neurons, hepatocytes
and enterocytes [85], and therefore further studies are
needed before potential therapeutic application.
A study on Pichia kudriavzevii RY55 found that mycocins
produced by this yeast species have growth inhibition effects
on potential bacterial pathogens, including E. coli, Entero-
coccus faecalis, Klebsiella spp., Staphylococcus aureus,
Pseudomonas aeruginosa and Pseudomonas alcaligenes.
However, the optimum temperature and pH for the toxins
were lower and higher, respectively, than in the normal
human gut environment. The maximum activity of the
enzyme was observed at 30

C and pH 5 [86]. Moreover, a
killer toxin produced by Candida krusei that was isolated
from fermented vegetables showed growth inhibition
towards E. coli, S. Typhimurium, S. aureus and Bacillus
cereus [87]. It has been reported that the killer toxin pro-
duced by Williopsis Saturnus shows a lack of bactericidal
activity against Streptococcus pneumoniae [88].
S. cerevisiae IFST062013 isolated from fruit juice demon-
strated moderate antibacterial activity compared to antibi-
otic doxycycline; the antagonistic effect was more
pronounced against Gram-negative than Gram-positive
bacteria. Moreover, a comparison of the effects of whole
cells, cells lysates and supernatants indicated that cell lysates
were more potent, which may be indicative of the antibacte-
rial properties coming from the cell components rather than
extracellular secretions. Nonetheless, the yeast species was
reported to produce killer toxin and siderophore, and
showed strong inhibition of bacterial biofilm
formation [89].
PREVENTION OF INVASIVENESS AND
SYSTEMIC INFECTION
The attachment of enteric bacterial pathogens, especially
Salmonella, to receptive epithelial cells leads to internaliza-
tion and hence infection, leading to symptoms and signs,
including diarrhoea, ulceration and the destruction of the
mucosa cells [29]. One of the mechanisms that has been
proposed to explain how probiotics prevent invasion is
competitive exclusion. This is defined as the ability of nor-
mal flora or probiotics, including yeast species, to limit the
colonization of GIT, competing with invading pathogens by
creating a restrictive physiological environment due to the
production of antagonistic molecules and competition for
binding sites and nutrients [90].
Lactobacillus kefiri CIDCA 8348, L. plantarum CIDCA
8327 and Kluveromyces marxianus var. marxianus CIDCA
8154 isolated from cheese whey fermented with kefir grain
reduced the invasiveness of Caco-2/TC7 cells by S.
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Enteritidis CIDCA 101. The precise mechanism and which
of the probiotic micro-organisms (if it was not a synergistic
effect) is responsible for the prevention of enterocyte inva-
sion could not be explicitly identified in the research, as the
three probiotic micro-organisms were used together [91].
S. boulardii prevented the invasiveness of S. Typhimurium
and subsequent translocation to the spleen and liver in
treated mice compared to untreated control mice, which
had high bacterial counts in these organs [65].
BIOFILM FORMATION INHIBITION
Biofilms are defined as communities of micro-organisms
attached to biotic or abiotic surfaces [68]. Bacterial biofilm
formation occurs in stages, including the reversible attach-
ment of bacterial cells on abiotic or biotic surfaces using
forces such van der Waal forces. This is followed by hydro-
philic/hydrophobic interactions between bacterial flagella,
fimbriae, LPS or adhesive proteins with the receptive surfa-
ces. When the bacteria have been irreversibly attached, the
production of extracellular polysaccharide (EPS) and extra-
cellular DNA proliferation occur. The final stage involves
the maturation of the biofilm and subsequent dispersal for
establishment at another site [92].
Biofilm formation in the GIT and other associated organs
such as the liver is one of the virulence factors of bacterial
pathogens, including enteropathogenic strains. It has been
reported that biofilms account for more than 60% of
microbial infections in humans, and these infections are
difficult to treat because of the antibiotic-resistant nature
of micro-organisms in biofilms [92]. Typhoidal Salmonella
infection, persistence and the asymptomatic carrier state
are associated with biofilm formation in the gallbladder
[93]. About 2–5% of typhoid patients developed persis-
tence and the asymptomatic carrier state as a result of bio-
film formation [94].
Alpha-amylase, an enzyme produced by yeast cells, has
been reported to prevent bacterial pathogen biofilm forma-
tion [92]. Moreover, other mechanisms, such as the creation
of restrictive physiological environment by probiotics, result
in competition for binding sites and nutrients, which also
prevents biofilm formation [90].
It has been reported that at 10, 20 and 100 µgml 1 doses of
alpha-amylase decreased S. aureus biofilm formation by
72%, 89 and 90% respectively, while it was able to reduce
matrix formation by 82% in an in vitro experiment [92].
S. cerevisiae and Saccharomyces kluyveri produce alpha-
amylase [95], and so yeast probiotics may potentially be
used to produce this enzyme to inhibit biofilm formation
and thus prevent carrier stage development in patients
infected with S. Typhi.
EFFECTS ON BACTERIAL TOXINS
Enteropathogenic bacteria, including Clostridium perfrin-
gens, S. aureus, Vibrio cholerae, Shigella dysenteriae, C. diffi-
cile and E. coli (Shiga toxin-producing), as well as
Salmonella species, produce toxins in the gastrointestinal
tract. The expression of the Salmonella enterotoxin (stn)
gene, which encodes a 29 kDa protein, is a hallmark of
S. Typhimurium virulence. The toxin is responsible for
symptoms that include nausea, vomiting, abdominal pain,
fever and diarrhoea [33, 96].
V. cholerae pathogenesis involves the activation of aden-
osine 3¢, 5¢-cyclic monophosphate (cAMP). Likewise,
adenylate cyclase in the cytoplasmic membrane in enter-
ocyte activation is mediated by Salmonella enterotoxins
which lead to a high concentration of adenosine mono-
phosphate [25]. This high concentration of adenosine
monophosphate causes a loss of intestinal fluid. S. bou-
lardii is reported to inhibit cholera toxin-stimulated
chloride secretion through the reduction of cAMP [97],
and therefore this ability of S. boulardii to inhibit chlo-
ride secretion and subsequent fluid loss due to V. chol-
erae toxin may well have similar effects on Salmonella-
associated diarrhoea, since Salmonella toxin is geneti-
cally, immunologically and functionally similar to
V. cholerae toxin [25, 97].
S. boulardii has been reported to deactivate or inhibit the
production of toxins by C. difficile and C. perfringens.
S. boulardii produces serine protease with proteolytic activ-
ity against C. difficile toxins [74]. Furthermore, S. boulardii
minimized the effects of toxin fluid secretion, decreased
mucosal permeability, decreased mucosal damage and
decreased the release of inflammatory cytokines when
administered to mice prior to them being given the V. chol-
erae toxin [74].
The ability of yeast to bind or neutralize bacterial toxin
is possibly probiotic strain-specific. S. cerevisiae LV02/
CNCM I-3856 provided no protection when porcine
IPEC-1 (intestinal epithelial cell lines 1) was infected
with enterotoxigenic E.coli. The integrity of the IPEC-1
barrier was disrupted, which indicates that this strain
does not act on the E.coli toxin [54].
LPS, an endotoxin of Salmonella and E.coli, is associated with
sepsis, which can be life-threatening [96]. Alkaline phospha-
tases, an enzyme produced by S. boulardii, was shown to neu-
tralize LPS and reduce its toxicity in a rat model, as well as
reducing inflammatory lesions and necrotic bodies in the liver
and heart of the treatment group compared to the control
group [98].
EFFECTS OF QUORUM SENSING ON
PATHOGENS
Micro-organisms produce extracellular compounds that mea-
sure microbial population density in the surrounding area
and, as a result, regulate their population. This phenomenon
is referred to as quorum sensing [99]. Quorum sensing in
poly-microbial populations has both synergistic and antago-
nistic effects. When quorum sensing compounds such as far-
nesol, N-Acyl homoserine lactones, tyrosol and dodecanol are
produced in sufficient quantities they cause the expression of
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genes within the population. Genes expression results in
microbial growth mode, virulence gene expression, biofilm
formation or morphological changes [3].
The quorum-sensing molecules produced by micro-organ-
isms not only affect poly-microbial communities, but also the
hosts. The immunomodulatory properties of farnesol have
been documented, including stimulation of the NF-kB path-
way through MEK1/2-ERK1/2-MSK1-dependent phosphory-
lation of p65, which leads to the production of cytokines,
namely IL-6 and IL-1a [3]. However, on a negative note, the
alteration of monocytes to dendritic cells by farnesol has been
reported. In brief, the effects of farnesol on immune cells lead
to reduced ability to recruit and activate T cells and hence
compromised immunity [3].
Farnesol, an alcohol derivative produced by S. cerevisiae or
C. albicans, has been shown to prevent bacterial biofilm for-
mation [3, 100]. Farnesol was reported to antagonize the pro-
duction of quinolone signal via the inhibition of
Pseudomonas quinolone signal gene A (PqsA). Furthermore,
farnesol has the potential to be used as a complementary
therapy for bacterial infections. It was shown to increase the
susceptibility of S. aureus to antibiotics and had synergistic
effects on the efficacy of nafcillin and vancomycin in the pre-
vention of biofilm formation by Staphylococcus epidermidis.
Additionally, farnesol enhanced the efficiency of B-lactams
against Burkholderia pseudomallei [3].
Anin vitro experiment in murine showed that macrophage
cell line RAW264.7 acted in synergy with farnesol and yeast
cell walls to increase the expression of pro-inflammatory
cytokines [3].
ANTIBACTERIAL PROPERTIES OF YEASTS
BIO-SURFACTANTS
Bio-surfactants, also referred to as glycolipids, are compounds
made up of one or two sugar molecules, especially glucose or
galactose residues in alpha or beta configuration on a lipid
backbone. Bio-surfactants are found in bacteria, fungi, plants
and animal cell membranes such as glycosylceramides, diacyl-
glycerolglycosides and sterylglycosides [101]. Bio-surfactants
are classified as rhamnolipids, sophorolipids, trehalolipids and
man-nosylerythritol lipids. These bio-surfactants are produced
by micro-organisms, some of which are probiotic bacteria or
yeasts [102, 103]. These bio-surfactants have been reported to
be functional in bioactive compounds such as glycosylcera-
mides, sphingolipids, glycosphingolipids, sphingosines and
ceramides. Their bioactivity has been associated with anti-pro-
liferative responses, such as the inhibition of cell growth, pro-
liferation, differentiation, interruption of the cell cycle, signal
transduction, senescence transformation, inflammation and
apoptosis [101].
Phytosphingosine, an endogenous bioactive molecule in
fungi, plant and human skins, has been shown to inhibit
Gram-positive bacteria growth and also has anti-inflamma-
tory properties. Moreover, sphingolipids such as cerebro-
sides and gangliosides have antibiotic properties, in that
they can bind pathogens or their toxins and remove them
from the GIT [101].
Biosurfactants have been reported to prevent pathogenic bac-
teria adhesion from infection sites as well as biofilm forma-
tion. Candida sphaerica UCP 0995 biosurfactant, also known
as lunasan, has anti-adhesive properties against some gram-
positive bacteria, including S. aureus and Streptococcus agalac-
tiae, while the polymeric biosurfactant produced by Candida
lipolytica UCP 0988 has anti-adhesive properties against
S. aureus, Lactobacillus casei, Streptococcus mutan and E. coli
[101]. Mannosylerthritol lipids (MEL) and cellobiose lipids
produced by fungi have antibacterial activities through the dis-
ruption of cell membranes, which leads to cell lysis. MEL types
A and B produced by Candida antarctica and Schizonella mel-
anogramma have antagonistic properties against gram-posi-
tive and gram-negative bacteria [101].
PROBLEMS ASSOCIATED WITH THE
PROPHYLACTIC AND THERAPEUTIC USE OF
PROBIOTICS
The safety of probiotic products is an important aspect that
needs consideration before they are used. S. boulardii is gen-
erally safe when used in a healthy population; however, in
2012, 100 cases of fungaemia were reported worldwide in
individuals with gastrointestinal track issues and those who
were immunocompromised [51]. Saccharomyces fungaemia
is critically severe in patients with gastrointestinal diseases
[51]. Moreover, an allergic reaction from the administra-
tion of S. boulardii was been reported in an infant who had
previously been diagnosed with food protein-induced
enterocolitis syndrome [104].
Candida species have also been reported to possess viru-
lence factors, including glycosidases, proteases, haemolysin,
lipases and phospholipases [105]. The ability of yeast spe-
cies to exist in a dimorphic form (e.g. through the forma-
tion of hyphae) has been reported to be one of their
virulence factors, and both the Saccharomyces and Candida
species have been shown to form hyphae [106]. The for-
mation of hyphae was found to be triggered by nutrient
deficiency, as well as the presence of 0.5% isoamyl alcohol
[107]. This is of great significance when kefir is used as a
probiotic. Kefir is a probiotic low-content alcoholic drink
[46], and therefore the potential for yeast species to
develop hyphae is a safety risk and needs further research.
Moreover, yeasts also have negative impacts on humans,
including being food spoilers [52].
Prophylactic and therapeutic use of probiotic bacteria in
infectious diseases caused by pathogens such as Salmonella
has some drawbacks due to the risk of multi-drug resistance
gene acquisition [45]. Antibiotic-resistant genes have been
detected in Enterococci and Lactobacillus lactis [74]. Both
Bacillus subtilis and E.coli Nissle 1917 are known to be sus-
ceptible to most antibiotic drugs and therefore pose no risk
of antibiotic resistance, and so are safe to use as probiotics
in prophylaxis, however their susceptibility to antibiotics
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makes these bacteria unsuitable for complementary therapy
in infectious bacteria treatment [108, 109]. Furthermore,
probiotic bacteria have been implicated in sepsis and endo-
carditis in patients who are immunosuppressed or predis-
posed to translocation and systemic dissemination of
bacteria [110]. These issues associated with probiotic bacter-
ia make their use less attractive in infectious bacterial dis-
eases and hence there is a need for alternative probiotic
micro-organisms.
EFFECTS OF PROBIOTIC PRODUCT
FORMULATION ON EFFICACY
Probiotics are commonly included in popular fermented
functional foods, such as yoghurt, milk, cheese, soybean,
fruits, sourdough, kefir and vegetable products, making their
consumption easier and more enjoyable, while at the same
time providing prophylactic and therapeutic benefits to con-
sumers [44–46]. Probiotic products can also be in the form
of lyophilized capsules or aqueous solutions. The survival of
probiotics in lyophilized form during delivery in in vivo
experiments has been reported to be higher than that
observed in the aqueous suspension form [48]. However, 7–
16 days at the optimum temperature (between 15–25

C) is
needed to resuscitate lyophilized yeasts cells. These require-
ments do not fit the temperature in the human GIT or the
time period that substances stay in there, which may make
the lyophilized yeast probiotic products less effective [48].
Furthermore, studies have shown that S. boulardii exhibited
different revival rates in lyophilized form (between 50 and
60%), whereas S. cerevisiae was found to have an even lower
revival rate of about 20% in aqueous solutions. These differ-
ences in the revival rates could be due to the different
freeze-drying methods used by different manufacturers.
Previous studies on S. boulardii and other Saccharomyces
species that examined survival and recovery from different
preserved forms showed diverse kinetics, such as viability
for long storage times, revival and survival in the GIT.
Despite this variability, lyophilization is the preferred
method of preservation [48].
CONCLUSION AND FUTURE PERSPECTIVES
Probiotic bacteria and yeasts are currently used for prophy-
laxis and complementary therapy against infectious and
non-infectious diseases. The rise of antibiotic resistance and
the potential of probiotic bacteria to carry antibiotic-resis-
tant genes, coupled with opportunistic pathogens, has
increased the need for alternative biotherapeutic drugs.
Yeast species isolated from various sources have antagonis-
tic properties against enteric bacterial pathogens. The antag-
onistic mechanisms have been reported in many in vitro
experiments and a few animal trials. The use of yeasts in
humans as s probiotic is very limited. Currently, S. boulardii
is the only probiotic yeast used for prophylaxis and therapies
in various ailments, but it has been implicated in fungaemia
and allergic reactions. Other yeast species with prophylactic
and therapeutic potential with respect to infectious diseases
such as Salmonella need further research.
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